Dapagliflozin Benefit Tempered by Cancer, Infection Rates
July 29, 2011|Family Practice News
Author and Disclosure Information
FROM THE ANNUAL SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION
Both the initial 52-week study and the 2-year extension trial were funded by BMS and AstraZeneca.
Dr. Nauck has been member on advisory boards or has consulted with AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Hoffman La Roche, Menarini/Berlin-Chemie, Merck, Sharp & Dohme, Novo Nordisk, and Versatis. He has received grant support from and served on the speakers bureau of Eli Lilly, Menarini/Berlin-Chemie, Merck, Sharp & Dohme as well as serving on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Hoffman La Roche, and Novo Nordisk.
